CAGT hero 2

Leading in the Development and Application of Genomic Technologies

Realizing the promise of the Genomic Revolution requires a quantum leap in the mechanistic understanding of disease biology and the discovery of drug targets. Remarkable recent innovations such as CRISPR-based genome editing, next-generation DNA sequencing, and high-throughput single-cell genomics have illuminated the path by which a technology-driven approach can inform, streamline, and accelerate drug target discovery. However, a cohesive effort is essentail to assimilate these otherwise disparate technologies and disease areas.

The Center for Advanced Genomic Technologies has assembled a team of world-leading engineers, scientists, and physicians to integrate these technologies, adapt them to help unravel disease biology, and discover new drug targets to catalyze a more robust biotechnology enterprise.

In the News

headshots of charlie gersbach and greg crawford

November 19, 2019

Greg Crawford and Charlie Gersbach Recognized as Highly Cited Researchers

Each year, the Web of Science Group identifies the world’s most influential researchers. The select few who have been most frequently cited by their peers over the last decade. In 2019, fewer than 6,300, or 0.1%, of the world's researchers, across 21 research fields, have earned this exclusive [...]

two strands of DNA

November 15, 2019 | BioSpace

Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, will collaborate to develop in vivo AAV-based therapies for up to eight central nervous system and neuromuscular targets.

Cartoon crystal structure of the TALEN gene editing technology. (Credit: Gersbach Lab)

November 4, 2019 | Duke Engineering News

The Evolution of Genetic Engineering

A Q&A with Charles Gersbach